What is Relay Therapeutics, Inc.'s change in deferred revenue?

Relay Therapeutics, Inc. (RLAY) reported change in deferred revenue of -$7.68M in Q1 2025.

How has Relay Therapeutics, Inc.'s change in deferred revenue changed year-over-year?

Relay Therapeutics, Inc.'s change in deferred revenue decreased by 500.0% year-over-year, from $1.92M to -$7.68M.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Relay Therapeutics, Inc. RLAY Change in Deferred Revenue

Change in Deferred Revenue at other companies

Ligand PharmaceuticalsLGND

$0+100%

Arcus BiosciencesRCUS

-$17M+39.3%

IDEAYA Biosciences, Inc.IDYA

-$587K—

Tango TherapeuticsTNGX

$0+100%

BridgeBio PharmaBBIO

-$2.38M+7.5%

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

Other financials

Income statement

See full

Revenue$3.0M-60.9%

Operating income-$78.6M+7.4%

Net income-$73.3M+4.9%

EPS (diluted)-$0.41+10.9%

Balance sheet

See full

Cash & equivalents$204.6M+119%

Total debt$31.6M-33.1%

Total equity$642.2M-10.9%

Total assets$699.6M-12.5%

Cash flow

See full

Operating cash flow-$51.1M+30.2%

CapEx$1.0K—

Free cash flow-$44.9M+22.5%

Valuation

See full

Market cap$3.8B+300%

Profitability

See full

Operating margin-2,776.6%-820pp

Net margin-2,554.1%-745pp

FCF margin-1,536%-429pp

Returns & leverage

See full

Return on equity-40%-4.3pp

Debt / equity0×0.0×

Current ratio22.1×+2.2×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s change in deferred revenue?: Relay Therapeutics, Inc. (RLAY) reported change in deferred revenue of -$7.68M in Q1 2025.
How has Relay Therapeutics, Inc.'s change in deferred revenue changed year-over-year?: Relay Therapeutics, Inc.'s change in deferred revenue decreased by 500.0% year-over-year, from $1.92M to -$7.68M.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.